Literature DB >> 4238453

Effect of tetrabenazine on extrapyramidal movement disorders.

M A Dalby.   

Abstract

Thirty patients with various extrapyramidal movement disorders were treated for prolonged periods with 75 to 225 mg. daily of tetrabenazine. In patients with choreiform and hemiballistic motor activity the involuntary movements were diminished or abolished. In patients with cerebellar or Parkinsonian tremor the tremor was aggravated in moderately severe cases, but was uninfluenced in severe cases. In all cases the dyskinesia returned when- the drug was stopped.Side-effects were inconsiderable and disappeared on reducing the dose slightly. Hence the drug may be an important alternative to neurosurgical treatment of hyperkinesias and especially suitable for severely disabled patients.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4238453      PMCID: PMC1983347          DOI: 10.1136/bmj.2.5654.422

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  11 in total

1.  [THE TREATMENT OF EXTRAPYRAMIDAL HYPERKINESIAS WITH SPECIAL REFERENCE TO HUNTINGTON'S CHOREA].

Authors:  H SATTES; E HASE
Journal:  Psychiatr Neurol Neurochir       Date:  1964 May-Jun

2.  Distribution of catechol compounds in human brain.

Authors:  I SANO; T GAMO; Y KAKIMOTO; K TANIGUCHI; M TAKESADA; K NISHINUMA
Journal:  Biochim Biophys Acta       Date:  1959-04

3.  [Treatment of Huntington's chorea].

Authors:  P GRUNG; P SUNDBY
Journal:  Tidsskr Nor Laegeforen       Date:  1957-02-15

4.  [Reserpine with Huntington's chorea; report of two cases].

Authors:  O FARBROT
Journal:  Tidsskr Nor Laegeforen       Date:  1956-09-15

5.  The effect of tetrabenazine in some hyperkinetic syndromes.

Authors:  H Pakkenberg
Journal:  Acta Neurol Scand       Date:  1968       Impact factor: 3.209

Review 6.  The biochemistry of dyskinesias.

Authors:  G Curzon
Journal:  Int Rev Neurobiol       Date:  1967       Impact factor: 3.230

7.  Localization of monoamines in the lower brain stem.

Authors:  A Dahlström; K Fuxe
Journal:  Experientia       Date:  1964-07-15

8.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704

9.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15

10.  [Treatment of Huntington's chorea with tetrabenazine (Nitoman)].

Authors:  B MOLLER-CHRISTENSEN; T VIDEBECH
Journal:  Ugeskr Laeger       Date:  1963-02-08
View more
  12 in total

1.  Hemiballismus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

2.  Biochemical mechanisms and management of choreiform movement disorders.

Authors:  L de Silva
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

3.  Tetrabenazine.

Authors:  Michael R Hayden; Blair R Leavitt; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

Review 4.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

5.  Treatment of involuntary movement disorders with tetrabenazine.

Authors:  M Swash; A H Roberts; H Zakko; K W Heathfield
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-04       Impact factor: 10.154

6.  Amine metabolites in the cerbrospinal fluid in Huntington's chorea.

Authors:  G Curzon; J Gumpert; D Sharpe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-08       Impact factor: 10.154

7.  Drug treatment of diseases characterized by abnormal movements.

Authors:  C D Marsden
Journal:  Proc R Soc Med       Date:  1973-09

Review 8.  Unintended effects of orphan product designation for rare neurological diseases.

Authors:  Sinéad M Murphy; Araya Puwanant; Robert C Griggs
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

Review 9.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 10.  VMAT2 Inhibitors in Neuropsychiatric Disorders.

Authors:  Arjun Tarakad; Joohi Jimenez-Shahed
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.